recent
studi
describ
sever
broadli
neutral
monoclon
antibodi
bnmab
recogn
glycandepend
epitop
gde
envelop
protein
recov
infect
subject
sever
eg
target
glycan
first
second
variabl
domain
domain
thought
play
import
role
conform
mask
antibodi
domain
recent
identifi
immun
respons
correl
protect
vaccin
trial
import
antibodi
polymer
glycan
well
establish
vaccin
target
bacteri
diseas
import
antibodi
glycan
vaccin
target
hiv
recent
recogn
antibodi
gde
may
particularli
signific
hiv
vaccin
base
molecular
mass
envelop
protein
contribut
nlink
carbohydr
howev
studi
report
antibodi
gde
human
anim
immun
candid
vaccin
report
describ
isol
mous
mab
immun
extracellular
domain
envelop
protein
epitop
map
use
glycopeptid
fragment
vitro
mutagenesi
show
bind
antibodi
depend
nlink
glycosyl
asparagin
number
domain
result
demonstr
addit
natur
infect
immun
recombin
protein
elicit
antibodi
gde
domain
although
littl
known
regard
condit
favor
antibodi
respons
gde
studi
demonstr
antibodi
aris
shortterm
immun
regimen
result
suggest
antibodi
gde
common
previous
suspect
analysi
antibodi
respons
envelop
protein
lead
discoveri
addit
antibodi
gde
recombin
form
envelop
env
protein
long
studi
hiv
vaccin
immunogen
env
protein
synthes
kda
precursor
undergo
matur
cleavag
yield
membranebound
protein
mediat
viru
fusion
peripher
membran
protein
respons
chemokin
receptor
bind
viru
tropism
viru
particl
envelop
protein
associ
noncoval
interact
form
trimer
spike
structur
highli
glycosyl
approxim
molecular
mass
attribut
nlink
glycosyl
sinc
possess
epitop
recogn
neutral
antibodi
multipl
vaccin
develop
effort
investig
immunogen
protein
howev
year
effort
none
candid
vaccin
describ
date
effect
elicit
broadli
neutral
antibodi
bnab
mani
year
inabl
elicit
bnab
attribut
inabl
accur
replic
trimer
structur
env
protein
found
surfac
virus
virusinfect
cell
howev
recent
discoveri
bnab
glycandepend
epitop
gde
monomer
rais
possibl
inabl
elicit
bnab
due
inabl
accur
replic
specif
glycan
structur
envelop
protein
surfac
virus
virusinfect
cell
inabl
direct
antibodi
respons
gde
inde
littl
known
immun
regimen
adjuv
formul
favor
format
antibodi
gde
particular
interest
gde
landscap
within
first
second
variabl
domain
although
domain
known
variabl
region
numer
glycosyl
site
within
domain
exhibit
high
degre
conserv
previous
thought
glycan
poorli
immunogen
characterist
addit
unusu
larg
number
glycosyl
site
thought
major
mechan
glycan
shield
respons
immun
escap
howev
recent
discoveri
bnmab
gde
suggest
epitop
immunogen
previous
imagin
vaccin
target
gde
might
help
overcom
problem
viru
variat
thu
begun
investig
magnitud
specif
frequenc
antibodi
gde
result
immun
recombin
env
protein
earli
stage
investig
antibodi
gde
envelop
protein
inform
howev
antibodi
domain
particular
interest
first
domain
contain
gde
recogn
sever
bnmab
eg
secondli
nonneutr
antibodi
domain
repres
antibodi
respons
found
correl
protect
hiv
vaccin
trial
includ
immun
alvachiv
canarypox
vector
vaccin
aidsvax
recombin
subunit
vaccin
lack
correl
neutral
antibodi
protect
trial
caus
investig
consid
numer
way
nonneutr
antibodi
domain
may
confer
protect
infect
method
may
involv
viral
inactiv
antibodydepend
cellmedi
viru
inhibit
virion
aggreg
inhibit
virion
mobil
transport
across
mucos
surfac
therefor
gde
domain
recogn
neutral
nonneutr
antibodi
repres
intrigu
target
candid
vaccin
prevent
infect
recombin
prepar
describ
previous
clinic
isol
sequenc
extracellular
domain
full
length
nine
overlap
fragment
creat
express
previous
describ
protein
contain
flag
epitop
herp
simplex
viru
glycoprotein
gd
fuse
amino
terminu
describ
previous
protein
purifi
immunoaffin
chromatographi
use
immunosorb
prepar
mab
gd
flag
epitop
point
mutat
introduc
fragment
mn
strain
sitedirect
mutagenesi
use
quikchang
lightn
kit
agil
santa
clara
ca
result
construct
verifi
confirmatori
sequenc
plasmid
protein
express
transfect
cell
invitrogen
carlsbad
ca
digest
enzym
peptidenglycosidas
f
pngase
f
use
remov
nlink
glycan
hiv
protein
fragment
enzym
respect
buffer
obtain
new
england
biolab
ipswich
mass
use
per
manufactur
instruct
briefli
recombin
fragment
denatur
denatur
buffer
sampl
boil
min
mix
reaction
buffer
unit
pngase
f
digest
carri
hr
confirm
digest
complet
digest
product
analyz
polyacrylamid
gel
electrophoresi
page
use
precast
polyacrylamid
gel
bistri
mop
run
buffer
invitrogen
protein
transfer
nitrocellulos
paper
novex
life
technolog
carlsbad
ca
mab
use
primari
antibodi
goat
antimous
iggm
conjug
hrp
american
qualex
antibodi
san
clement
ca
use
secondari
antibodi
glycanindepend
control
mab
includ
antigd
balbc
mice
charl
river
hollist
ca
initi
immun
incorpor
freund
complet
adjuv
boost
multipl
time
four
week
period
immunogen
incorpor
freund
incomplet
adjuv
splenocyt
harvest
immun
mice
fuse
mous
cell
line
creat
immort
hybridoma
cell
line
use
standard
procedur
identifi
antibodi
bound
region
hybridoma
select
use
hat
media
hybridoma
subclon
screen
secret
antibodi
reactiv
gdtag
hybridoma
supernat
test
posit
reactiv
enzymelink
immunosorb
assay
elisa
subclon
secret
mab
character
elisa
assay
carri
flat
bottom
well
microtit
plate
nunc
affymetrix
santa
clara
ca
coat
protein
pb
overnight
hr
plate
block
pb
contain
bsa
sodium
azid
hr
room
temperatur
hr
pb
solut
remov
plate
wash
four
time
initi
screen
hybridoma
supernat
obtain
directli
well
cultur
plate
ad
plate
plate
incub
gentl
agit
hr
room
temperatur
wash
four
time
pb
incub
hr
room
temperatur
goatantimous
goatantihuman
hrpconjug
antibodi
jackson
immunoresearch
laboratori
west
grove
pa
plate
wash
four
time
tbst
plate
develop
opd
solut
stop
h
absorb
read
isotyp
mab
determin
use
pierc
rapid
elisa
mous
antibodi
isotyp
kit
thermo
fisher
scientif
inc
rockford
il
elisa
use
detect
antibodi
bind
clade
b
c
isol
overlap
fragment
fragment
use
studi
similar
describ
previous
epitop
map
use
librari
overlap
peptid
amino
acid
length
deriv
mn
sequenc
nih
aid
reagent
program
germantown
md
catalog
number
peptid
elisa
perform
initi
coat
peptid
subsequ
step
follow
elisa
describ
antibodi
bind
peptid
test
duplic
mab
use
competit
assay
purchas
polymun
scientif
klosterneuburg
austria
tzmbl
neutral
assay
use
evalu
neutral
potenti
mab
describ
paper
virus
use
assay
clade
c
isol
clade
b
isol
mn
jrfl
plasmid
construct
pseudovirus
except
kindli
provid
dr
david
montefiori
duke
univers
durham
nc
posit
control
use
viru
neutral
assay
consist
mixtur
monoclon
antibodi
trimab
sequenc
compar
studi
align
use
mafft
number
amino
acid
describ
paper
provid
use
standard
refer
sequenc
lo
alamo
nation
laboratori
hiv
sequenc
compendium
lo
alamo
nm
hivlanlgovcontentsequencehivcompendiumhtml
previou
studi
character
envelop
protein
clade
b
clinic
isol
isol
contain
point
mutat
appear
increas
neutral
sensit
broadli
neutral
monoclon
polyclon
antibodi
destabil
prehairpin
fusion
intermedi
postul
immun
envelop
protein
might
provid
access
epitop
eg
membran
proxim
extern
region
mper
normal
conceal
format
coiledcoil
structur
trigger
engag
chemokin
receptor
although
immun
prepar
envelop
protein
result
antibodi
except
neutral
activ
mous
hybridoma
isol
reagent
investig
antibodi
respons
uniqu
structur
featur
molecul
map
epitop
recogn
mab
secret
hybridoma
seri
glycopeptid
fragment
prepar
design
contain
overlap
sequenc
similar
previous
describ
fig
supplementari
fig
briefli
fragment
sequenc
design
contain
consecut
constant
variabl
domain
hiv
smallest
fragment
contain
domain
supplementari
fig
largest
fragment
includ
sequenc
domain
domain
supplementari
fig
construct
append
ntermin
gd
flag
epitop
purif
purpos
express
transient
transfect
cell
order
maintain
much
tertiari
structur
possibl
construct
design
preserv
disulfid
bridg
found
fulllength
describ
previous
fragment
express
approach
typic
glycosyl
maintain
disulfid
structur
requir
recognit
varieti
conformationdepend
mab
analysi
mab
bind
panel
six
differ
fragment
fig
supplementari
fig
panel
af
led
discoveri
hybridoma
clone
mab
clone
found
bind
fragment
contain
domain
includ
short
fragment
includ
domain
fig
supplementari
fig
contrast
bind
two
fragment
lack
domain
fig
data
suggest
recogn
epitop
locat
within
domain
isotyp
analysi
reveal
belong
subclass
data
shown
order
map
epitop
attempt
measur
antibodi
bind
seri
overlap
synthet
peptid
amino
acid
length
domain
mn
strain
nih
aid
reagent
program
synthet
peptid
contain
neither
glycosyl
disulfid
structur
present
secret
fragment
use
initi
screen
contrast
rabbit
antibodi
bound
multipl
peptid
unabl
bind
synthet
peptid
panel
supplementari
tabl
result
suggest
might
recogn
conformationdepend
epitop
investig
possibl
measur
bind
nativ
reduc
carboxymethyl
rcm
form
domain
supplementari
fig
panel
g
surprisingli
found
bound
nativ
rcm
mn
fragment
fig
result
demonstr
recogn
conformationindepend
epitop
domain
mn
observ
bound
rcm
form
mn
synthet
peptid
indic
factor
conform
requir
bind
hypothes
bind
may
depend
glycosyl
present
fragment
express
mammalian
cell
synthet
peptid
local
epitop
recogn
evalu
abil
bind
panel
seventeen
purifi
divers
sequenc
express
mammalian
cell
fig
includ
eleven
clade
b
includ
mn
iiib
jrfl
wito
five
clinic
isol
addit
measur
bind
five
clade
c
describ
previous
test
eight
clade
b
sequenc
bound
antibodi
fig
local
epitop
recogn
sequenc
bind
nonbind
envelop
protein
align
amino
acid
sequenc
compar
identifi
polymorph
segreg
bind
fig
sequenc
align
implic
sever
predict
nlink
glycosyl
site
pngss
present
bound
present
unabl
bind
promis
site
comparison
asparagin
posit
note
clade
b
sequenc
jrfl
contain
residu
lack
requir
serin
threonin
canon
nxst
motif
necessari
nlink
glycosyl
therefor
mab
depend
glycosyl
would
expect
bind
jrfl
vitro
mutagenesi
studi
carri
investig
depend
bind
posit
prevent
glycosyl
posit
independ
substitut
either
n
canon
nxt
nlink
glycosyl
motif
first
replac
n
posit
histidin
h
examin
multipl
hiv
sequenc
data
set
reveal
histidin
second
common
amino
acid
posit
n
result
studi
shown
fig
found
replac
n
h
posit
complet
abolish
bind
fragment
confirm
find
replac
threonin
posit
alanin
independ
construct
substitut
also
disrupt
png
abolish
bind
fragment
fig
contrast
neither
mutat
effect
bind
posit
control
mab
whose
bind
establish
independ
glycosyl
togeth
studi
indic
bind
depend
png
posit
verifi
recogn
glycandepend
epitop
treat
mn
fragment
peptidenglycosidas
f
pngase
f
enzym
cleav
nlink
glycan
first
nacetylglucosamin
glcnac
effect
remov
carbohydr
glycoprotein
elisa
assay
fig
observ
pngase
treatment
destroy
bind
mab
mn
domain
fragment
confirm
pngase
treatment
ran
complet
verifi
ident
speci
bound
immunoblot
studi
carri
experi
mockand
enzymetr
protein
probe
either
fig
antigd
control
mab
fig
observ
nativ
mocktreat
fragment
exhibit
molecular
mass
higher
expect
approxim
kda
anomal
migrat
attribut
high
carbohydr
content
domain
contain
pngss
amino
acid
includ
gd
tag
expect
treatment
pngase
f
result
molecular
mass
consist
calcul
valu
result
suggest
recogn
gde
domain
recent
structur
studi
shown
domain
form
structur
differ
strand
identifi
b
c
fig
observ
locat
near
middl
strand
locat
cystein
form
disulfid
bond
cystein
b
strand
respect
comparison
sequenc
show
glycan
conserv
among
clade
b
virus
examin
structur
domain
show
locat
close
spatial
proxim
glycosyl
site
critic
bind
broadli
neutral
mab
fig
howev
measur
bind
envelop
protein
lack
glycosyl
site
bind
appear
unaffect
data
shown
abil
neutral
variou
clade
b
c
virus
determin
tzmbl
neutral
assay
found
abl
neutral
clade
b
isol
mn
jrfl
clade
c
isol
supplementari
tabl
examin
sequenc
virus
show
jrfl
contain
glycosyl
site
studi
document
isol
mous
mab
novel
gde
domain
hiv
envelop
protein
four
new
find
deriv
studi
first
show
antibodi
gde
domain
result
immun
recombin
wherea
previous
antibodi
isol
hivinfect
human
chimpanze
second
show
antibodi
gde
result
rel
short
immun
schedul
continu
exposur
long
period
time
occur
chronic
hiv
infect
requir
elicit
antibodi
gde
third
show
epitop
common
among
clade
b
virus
final
show
bind
gde
domain
bind
suffici
viru
neutral
addit
factor
determin
whether
antibodi
possess
viru
neutral
activ
histor
nlink
glycan
consid
poorli
immunogen
surpris
discov
larg
percentag
broadli
neutral
antibodi
sera
hivinfect
individu
direct
gde
well
document
nlink
glycan
found
hiv
envelop
protein
function
glycan
shield
protect
larg
region
structur
antibodi
bind
steric
hindranc
know
shield
imperfect
glycan
becom
target
neutral
antibodi
recent
studi
mab
hivinfect
human
identifi
least
two
differ
clonal
lineag
bnab
recogn
gde
domain
includ
lineag
recogn
glycan
posit
lineag
recogn
glycan
posit
thu
far
antibodi
human
recogn
gde
describ
howev
recent
pepscan
analysi
clinic
specimen
vaccin
trial
reveal
portion
domain
contain
png
highli
immunogen
observ
site
contain
within
region
particularli
visibl
humor
immun
respons
support
hypothesi
antibodi
gde
may
addit
found
human
sera
studi
show
gde
major
target
bnab
prompt
consider
interest
develop
vaccin
abl
elicit
antibodi
class
epitop
howev
numer
uncertainti
remain
concern
best
approach
elicit
antibodi
gde
know
littl
regard
optim
formul
immun
regimen
elicit
antibodi
gde
human
bnab
gde
seldom
found
year
postinfect
follow
year
continu
exposur
viral
antigen
base
kinet
postul
antibodi
gde
might
occur
result
continu
exposur
highli
glycosyl
viral
antigen
consequ
breakdown
immun
toler
glycan
structur
result
hiv
infect
inde
sever
group
pursu
possibl
guid
immun
strategi
viral
protein
recov
sequenti
viru
isol
thought
guid
evolut
antibodi
gde
broadli
neutral
activ
postul
approach
might
effect
drive
evolut
antibodi
atyp
structur
found
bnab
long
cdr
domain
amino
acid
result
unusu
vdj
splice
highli
mutat
antibodi
gene
nucleotid
chang
result
unusu
high
level
somat
mutat
moreov
bnab
gde
often
appear
bind
simultan
two
differ
glycan
moieti
eg
case
case
isol
demonstr
antibodi
gde
aris
healthi
uninfect
anim
result
short
intens
immun
regimen
recombin
envelop
protein
work
sequenc
solv
structur
antibodi
would
provid
insight
whether
inabl
neutral
hiv
result
lack
structur
featur
eg
long
cdr
domain
etc
common
bnab
final
studi
highlight
possibl
antibodi
gde
common
previous
appreci
insight
implic
understand
protect
immun
respons
highli
glycosyl
protein
pathogen
cytomegaloviru
sarscov
influenza
west
nile
viru
recent
vaccin
develop
epitop
primarili
amino
acid
carbohydr
combin
appear
anoth
import
class
epitop
exist
exemplifi
bnab
hiv
depend
amino
acid
nlink
glycan
contact
studi
evalu
frequenc
specif
antibodi
well
studi
aim
elucid
best
method
elicit
antibodi
may
present
import
medic
insight
applic
refer
web
version
pubm
central
supplementari
materi
monoclon
antibodi
recogn
glycandepend
epitop
hiv
bind
depend
glycan
posit
domain
glycandepend
antibodi
aris
short
immun
schedul
glycandepend
antibodi
may
common
previous
expect
structur
studi
may
provid
insight
lack
neutral
activ
map
epitop
use
gdtag
fragment
bind
variou
fragment
envelop
protein
assay
elisa
fragment
bound
posit
control
antibodi
gd
tag
amino
acid
sequenc
align
domain
use
bind
studi
bind
differ
isol
measur
elisa
abl
bind
indic
plu
sign
unabl
bind
indic
minu
sign
sequenc
align
use
mafft
locat
pngss
match
pattern
bind
indic
white
black
letter
locat
predict
glycosyl
site
fail
match
pattern
bind
indic
black
blue
letter
number
provid
refer
standard
sequenc
diagram
domain
structur
domain
report
mclellan
et
al
modifi
show
approxim
locat
glycosyl
site
red
segment
recogn
mab
broadli
neutral
mab
letter
ad
indic
strand
structur
two
disulfid
bond
posit
flank
glycosyl
site
also
indic
yellow
featur
includ
bc
connect
peptid
requir
bind
also
shown
